METHODS OF TREATING SEPSIS WITH SYNAPTIC VESICLE 2A AND/OR 2B BINDING CHEMICAL ENTITIES
Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam.
1 - 22 . (canceled)
23 . A method for preventing or treating sepsis induced acute brain dysfunction (SiBD) comprise administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis.
24 . The method of claim 23 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator.
25 . The method of claim 23 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam.
26 . The method of claim 23 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered at a dose of from 5 mg/kg to 100 mg/kg per day for at least two days.
27 . The method of claim 26 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered at a dose of from 15 mg/kg to 50 mg/kg per day for at least two days.
28 . The method of claim 23 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered every twelve hours.
29 . The method of claim 26 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered at a dose of 15 mg/kg every twelve hours.
30 . The method of claim 23 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered for at least four days.
31 . The method of claim 30 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered for at least one week.
32 . The method of claim 30 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered for at least two weeks.
33 . The method of claim 30 , wherein the synaptic vesicle 2a and/or 2b binding chemical entity is administered for at least four weeks.
34 . The method of claim 25 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered at a dose of from 5 mg/kg to 100 mg/kg per day for at least two days.
35 . The method of claim 34 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered at a dose of from 15 mg/kg to 50 mg/kg per day for at least two days.
36 . The method of claim 25 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered every twelve hours.
37 . The method of claim 36 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered at a dose of 15 mg/kg every twelve hours.
38 . The method of claim 25 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered for at least four days.
39 . The method of claim 39 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered for at least one week.
40 . The method of claim 39 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered for at least two weeks.
41 . The method of claim 39 , wherein levetiracetam or a derivative or analogue of levetiracetam is administered for at least four weeks.